Freestone Grove Partners LP Invests $9.40 Million in Baxter International Inc. $BAX

Key Points

• Freestone Grove Partners acquired 440,951 Baxter International shares worth approximately $9.4 million, representing about 0.09% of the company. Institutional investors collectively own 90.19% of BAX.
• Baxter exceeded quarterly earnings expectations, reporting $0.56 in EPS versus the $0.37 consensus estimate and $2.96 billion in revenue, up 5.3% year over year. The company reiterated fiscal 2026 EPS guidance of $1.95–$2.15.
• Analyst sentiment remains mostly neutral, with a consensus “Hold” rating and an average price target of $22.45, below the reported share price of $25.97. Baxter also declared a quarterly dividend of $0.01 per share, yielding approximately 0.2%.

Freestone Grove Partners LP purchased a new position in Baxter International Inc. (NYSE:BAX - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 440,951 shares of the medical instruments supplier's stock, valued at approximately $9,401,000. Freestone Grove Partners LP owned about 0.09% of Baxter International as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Basepoint Wealth LLC bought a new stake in shares of Baxter International during the fourth quarter worth $26,000. Jones Financial Companies Lllp bought a new position in shares of Baxter International in the second quarter worth about $26,000. Imprint Wealth LLC purchased a new position in Baxter International in the 3rd quarter worth about $27,000. MUFG Securities EMEA plc purchased a new position in Baxter International in the 2nd quarter worth about $46,000. Finally, Los Angeles Capital Management LLC bought a new stake in Baxter International during the 4th quarter valued at about $46,000. 90.19% of the stock is owned by hedge funds and other institutional investors.

Baxter International Stock Performance

Shares of BAX stock opened at $25.97 on Friday. The firm has a market cap of $13.43 billion, a price-to-earnings ratio of -12.55, a PEG ratio of 4.01 and a beta of 0.60. Baxter International Inc. has a 52-week low of $15.73 and a 52-week high of $30.00. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 1.39. The company's 50 day moving average is $24.12 and its 200 day moving average is $20.51.

Baxter International (NYSE:BAX - Get Free Report) last announced its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. The business had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The firm's revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.59 earnings per share. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, sell-side analysts anticipate that Baxter International Inc. will post 2.04 EPS for the current fiscal year.

Baxter International Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International's dividend payout ratio is currently -1.93%.

Analyst Upgrades and Downgrades

BAX has been the subject of several research reports. UBS Group boosted their price objective on shares of Baxter International from $19.00 to $25.00 and gave the company a "hold" rating in a research report on Tuesday, July 28th. Wall Street Zen raised shares of Baxter International from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Zacks Research raised shares of Baxter International from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. The Goldman Sachs Group increased their price objective on Baxter International from $19.00 to $21.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Finally, Barclays raised their price objective on Baxter International from $25.00 to $27.00 and gave the stock an "overweight" rating in a report on Friday, May 1st. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Baxter International has a consensus rating of "Hold" and an average target price of $22.45.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source